FBXO28: A Potential Drug Target and Biomarker (G23219)

Target Name: FBXO28

NCBI ID: G23219

FBXO28

FBXO28: A Potential Drug Target and Biomarker

Furin-type serine proteases (FBPases) are a family of enzymes that are involved in a variety of cellular processes, including cell signaling, intracellular signaling, and tissue repair. Among these enzymes is FBXO28 (FLJ10766), a furin-type serine protease that is expressed in various tissues and cells, including liver, pancreas, and heart. FBXO28 has been identified as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

FBXO28 is a 21-kDa protein that is characterized by its unique catalytic mechanism. It uses a specific tryptophan residue as a suicide substrate to initiate the proteolytic cleavage. This mechanism allows the enzyme to selectively target and cleave specific proteins, including its own subunit, suggesting that it may have self-cleavage properties. The active site of FBXO28 is composed of a catalytic tunnel, a 尾-sheet, and a carboxylic acid side chain, which provides a favorable substrate for the tryptophan residue.

FBXO28 has been shown to play a role in a variety of cellular processes. In the liver, it is involved in the detoxification of xenobiotics and other harmful substances. In the pancreas, it is involved in the processing of insulin and other hormones. In the heart, it has been shown to regulate contractility and heart rate.

FBXO28 has also been identified as a potential drug target for several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and the accumulation of neurofibrillary tangles, which are thought to be caused by the misfolding and aggregation of specific proteins, including FBXO28.

In addition to its potential therapeutic applications, FBXO28 has also been identified as a potential biomarker for several diseases. For example, it has been shown to be elevated in the brains of individuals with Alzheimer's disease, and it has been used as a diagnostic marker for neurodegenerative diseases. In addition, FBXO28 has been shown to be expressed in the blood vessels of individuals with neurodegenerative diseases, which suggests that it may be a useful biomarker for tracking the progression of these conditions.

FBXO28 is also of interest as a potential target for drug development for various diseases. For example, several drugs that have been shown to inhibit FBXO28 have been shown to be effective in treating neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These drugs work by inhibiting the activity of FBXO28 and preventing it from cleaving and damaging specific proteins.

In conclusion, FBXO28 is a unique and promising protein that has the potential to be a drug target and biomarker for a variety of diseases. Its unique catalytic mechanism and its involvement in various cellular processes make it an attractive target for drug development. Further research is needed to fully understand the role of FBXO28 in disease and to develop effective treatments for neurodegenerative diseases.

Protein Name: F-box Protein 28

Functions: Probably recognizes and binds to some phosphorylated proteins and promotes their ubiquitination and degradation

The "FBXO28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXO28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets